On June 24, 2024, Vico Therapeutics B.V. closed the transaction. The company raised ?11.5 million ($12.4 million) in its second and final tranche, bringing total funding raised in the transaction to ?65.8 million ($72.4 million) co-led by new investor, Seroba Life Sciences Limited and existing investor, Kurma Partners.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
168.5 EUR | +0.60% |
|
+0.18% | +6.17% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+6.17% | 5.87B | |
-7.83% | 63.77B | |
+2.68% | 60.07B | |
+19.49% | 37.75B | |
+8.32% | 29.8B | |
+14.54% | 29.42B | |
+17.27% | 19.95B | |
+8.10% | 19.53B | |
+73.03% | 17.52B | |
+27.59% | 15.77B |
- Stock Market
- Equities
- ACKB Stock
- News Ackermans & van Haaren NV
- Vico Therapeutics B.V. announced that it has received ?65.8 million in funding from a group of investors